From the creation of our technology, to its current cutting edge applications
The BioLoomics biosensor technology was initially developed at the University of Colorado Boulder as a component of the Rapid Threat Assessment (RTA) project, funded by DARPA.
While building pipelines to rapidly understand the effects of chemical and biochemical threats on living cells, we began utilizing genetically encoded Forster Resonance Energy Transfer (FRET) biosensors in cells to assess each threat’s effect on biochemical pathways.
We realized this technology could be applied broadly to the pharmaceutical industry, provided that large libraries of biosensors with pathway specificity and high dynamic range were available. Since relatively few biosensors exist with these features, we began testing strategies to generate biosensor libraries and to rapidly assign biosensors to their analytic capabilities in an unbiased way.
We began this journey at CU Boulder and formed BioLoomics, Inc., to commercialize our cutting edge ideas. Using our ever growing toolbox of biosensor genes, we aim to rapidly assess drug effects for our clients, to improve the clinical success of their drug development pipelines.